Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Cash from Financing Activities of $847000.0 for Q1 2026, down 99.52% year-over-year from $178.1 million in Q1 2025, and up 700.71% quarter-over-quarter from -$141000.0 in Q4 2025.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Cash from Financing Activities for 10 consecutive years, with $847000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 99.52% year-over-year to $847000.0; the TTM figure through Mar 2026 stood at -$3.9 million (down 101.12% YoY), while the FY2025 annual figure was $173.4 million, up 0.96% from the prior year.
- Cash from Financing Activities improved to $847000.0 in Q1 2026 per TECX's latest filing, from -$141000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $179.7 million in Q2 2024 and bottomed at -$6.3 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $22.3 million across 5 years, with a median of $1000.0 in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 57747.46% in 2023 and fell as far as 32500.0% in 2023.
- Tectonic Therapeutic's Cash from Financing Activities stood at $59000.0 in 2022, then soared by 57747.46% to $34.1 million in 2023, then tumbled by 103.13% to -$1.1 million in 2024, then jumped by 86.81% to -$141000.0 in 2025, then jumped by 700.71% to $847000.0 in 2026.
- Business Quant data shows TECX's Cash from Financing Activities at $847000.0 in Q1 2026, -$141000.0 in Q4 2025, and -$457000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Tectonic Therapeutic | 589.02 Mn | 589.02 Mn | - | 11.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.68 Mn |
| Mar 31, 2026 | 847,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Sep 30, 2025 | -457,000.00 |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | 178.12 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | 179.74 Mn |
| Mar 31, 2024 | -668,000.00 |
| Dec 31, 2023 | 34.13 Mn |
| Sep 30, 2023 | -114,000.00 |
| Jun 30, 2023 | -324,000.00 |
| Mar 31, 2023 | 55,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2021 | 14.95 Mn |
| Sep 30, 2021 | 22,000.00 |